Stock Analysis

Krsnaa Diagnostics First Quarter 2025 Earnings: Revenues Disappoint

NSEI:KRSNAA
Source: Shutterstock

Krsnaa Diagnostics (NSE:KRSNAA) First Quarter 2025 Results

Key Financial Results

  • Revenue: ₹1.78b (up 27% from 1Q 2024).
  • Net income: ₹179.2m (up 22% from 1Q 2024).
  • Profit margin: 10% (in line with 1Q 2024).
  • EPS: ₹5.50 (up from ₹4.66 in 1Q 2024).
earnings-and-revenue-growth
NSEI:KRSNAA Earnings and Revenue Growth August 8th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Krsnaa Diagnostics Revenues Disappoint

Revenue missed analyst estimates by 2.7%. Earnings per share (EPS) was mostly in line with analyst estimates.

Looking ahead, revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Healthcare industry in India.

Performance of the Indian Healthcare industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with Krsnaa Diagnostics.

Valuation is complex, but we're here to simplify it.

Discover if Krsnaa Diagnostics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.